Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

Clinical trial NCT07284433 · RECRUITING

Trial details

NCT number: NCT07284433
Sponsor: AvenCell Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Lymphoma Diffuse Large B-cell Leukemia and Lymphoma Leukemia Relapse Lymphoma Receiving CAR-T Therapy

Start date: 2026-01-06
Primary completion: 2029-04-27
Enrollment: 178

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.